Myomo Q1 2026: Revenue Growth Continues but Cash Burn Persists

What happened

Myomo reported Q1 2026 financial results, showing continued revenue growth driven by the Medicare brace-benefit reclassification, but the company remains unprofitable with ongoing operating cash outflows. The company highlighted four success pillars for 2026, including growing recurring revenue and expanding market access, yet liquidity remains a concern given ~$15.5 million in cash and short-term investments as of mid-2025 and accelerating cash burn in the first half of the year. The material weakness in internal controls over financial reporting is still under remediation, adding governance risk. While the Medicare fee schedule provides a structural tailwind, the company has not demonstrated sustainable unit economics or a path to profitability. The investment case hinges on execution, claim approval rates, and avoiding dilution, none of which were resolved in Q1.

Implication

Myomo's growth under the Medicare brace benefit is encouraging, but the company must prove it can achieve operating breakeven without further equity dilution. Unless cash generation improves markedly or a clear path to profitability emerges, the stock is a show-me story. Investors should watch for stabilization of operating cash flow and completion of ICFR remediation before considering a more bullish stance.

Thesis delta

The Q1 2026 results reinforce existing HOLD thesis: revenue traction persists but cash burn and scale challenges remain unchanged, with no catalyst to shift the neutral stance.